ICON plc has signed a three-year agreement with Pfizer to provide global services for planning, execution, management and conduct of clinical trials. Pfizer has the right to extend the term for an additional two years. Financial details were not disclosed.
 
Ciaran Murray, ICON’s chief executive officer, said, “The progression of our relationship with Pfizer is a recognition of ICON’s capabilities in supporting drug development efforts. We look forward to continuing our relationship with Pfizer to help advance its development pipeline and innovation in the drug development process.”